유전자 편집 기술 시장 : 세계 산업 규모, 점유율, 동향, 경쟁, 기회, 예측 - 제공 내용별, 기술별, 용도별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

The Global Gene Editing Technologies Market, valued at USD 5.78 Billion in 2024, is projected to experience a CAGR of 10.30% to reach USD 10.41 Billion by 2030. Gene editing technologies encompass methods enabling highly specific changes to an organism's DNA, facilitating the precise addition, removal, or alteration of genetic material at targeted genomic locations. The market's growth is primarily driven by continuous technological advancements, the expanding utility of gene editing across diverse applications, and increasing demand for personalized medicine. Furthermore, the rising global prevalence of genetic and chronic disorders, coupled with substantial government funding for related research, significantly contributes to market expansion.

Key Market Drivers

The global gene editing technologies market is profoundly influenced by continuous advancements in the precision and scope of gene editing tools. Innovations consistently emerge, enhancing the safety and accuracy of genetic modifications. For example, according to Massachusetts Institute of Technology, October 10, 2025, "MIT's new precision gene editing tool could transform medicine," a new system makes 60 times fewer mistakes than previous iterations, significantly improving targeting capabilities. These technological refinements directly enable the expanding therapeutic and research applications of gene editing. As tools become more reliable, the range of treatable diseases broadens, and the feasibility of complex genetic interventions increases. This expansion is evident in the burgeoning clinical pipeline.

Key Market Challenges

Persistent concerns regarding off-target effects present a significant impediment to the growth of the Global Gene Editing Technologies Market. These effects, where unintended genetic alterations occur at locations other than the targeted site, introduce substantial safety risks for patients. Such unpredictable outcomes necessitate extensive preclinical and clinical scrutiny, prolonging development timelines and increasing research expenditures. The inherent unpredictability associated with off-target editing directly influences regulatory bodies' cautious approach to product approvals, leading to more stringent testing requirements and extended observational periods for gene-edited therapies.

The impact of these safety concerns is reflected in development setbacks.

Key Market Trends

Accelerated Development of In Vivo Gene Therapies is a significant trend, representing a critical shift towards direct administration of genetic material into the body, thereby bypassing complex *ex vivo* cell manipulation. This approach offers broader therapeutic applicability, simpler administration, and reduced manufacturing complexities, particularly for systemic diseases or difficult-to-access tissues. According to Towards Healthcare, the *in vivo* gene therapy segment constituted approximately 55% of the gene therapy clinical trials market in 2024, indicating its substantial and growing prevalence. This modality is accelerating clinical development pathways.

Key Market Players

• Addgene Inc.
• BRAIN Biotech AG
• Cellectis S.A.
• Creative Biolabs, Inc.
• CRISPR Therapeutics AG
• BioRad Laboratories, Inc.
• DNA Script SAS
• GeneCopoeia, Inc.
• Merck KGaA
• PerkinElmer Inc.

Report Scope:

In this report, the Global Gene Editing Technologies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Editing Technologies Market, By Offerings:

• Gene Editing Products
• Gene Editing Services

Gene Editing Technologies Market, By Technology:

• CRISPR Gene Editing Technology
• Non-CRISPR Gene Editing Technology

Gene Editing Technologies Market, By Application:

• Agricultural
• Biomedical

Gene Editing Technologies Market, By End User:

• Academic Institutes and Research Centers
• Life Sciences Companies
• Contract Research Organizations (CROs)/ Contract Manufacturing Organizations (CMOs)

Gene Editing Technologies Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Gene Editing Technologies Market.

Available Customizations:

Global Gene Editing Technologies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Gene Editing Technologies Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Offerings (Gene Editing Products, Gene Editing Services)
  • 5.2.2. By Technology (CRISPR Gene Editing Technology, Non-CRISPR Gene Editing Technology)
  • 5.2.3. By Application (Agricultural, Biomedical)
  • 5.2.4. By End User (Academic Institutes and Research Centers, Life Sciences Companies, Contract Research Organizations (CROs)/ Contract Manufacturing Organizations (CMOs))
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Gene Editing Technologies Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Offerings
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Gene Editing Technologies Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Offerings
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Gene Editing Technologies Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Offerings
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Gene Editing Technologies Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Offerings
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End User

7. Europe Gene Editing Technologies Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Offerings
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Gene Editing Technologies Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Offerings
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End User
  • 7.3.2. France Gene Editing Technologies Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Offerings
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End User
  • 7.3.3. United Kingdom Gene Editing Technologies Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Offerings
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End User
  • 7.3.4. Italy Gene Editing Technologies Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Offerings
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Gene Editing Technologies Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Offerings
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End User

8. Asia Pacific Gene Editing Technologies Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Offerings
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Gene Editing Technologies Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Offerings
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End User
  • 8.3.2. India Gene Editing Technologies Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Offerings
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Gene Editing Technologies Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Offerings
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Gene Editing Technologies Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Offerings
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Gene Editing Technologies Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Offerings
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End User

9. Middle East & Africa Gene Editing Technologies Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Offerings
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Gene Editing Technologies Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Offerings
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End User
  • 9.3.2. UAE Gene Editing Technologies Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Offerings
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End User
  • 9.3.3. South Africa Gene Editing Technologies Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Offerings
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End User

10. South America Gene Editing Technologies Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Offerings
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Gene Editing Technologies Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Offerings
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End User
  • 10.3.2. Colombia Gene Editing Technologies Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Offerings
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End User
  • 10.3.3. Argentina Gene Editing Technologies Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Offerings
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Gene Editing Technologies Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Addgene Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. BRAIN Biotech AG
• 15.3. Cellectis S.A.
• 15.4. Creative Biolabs, Inc.
• 15.5. CRISPR Therapeutics AG
• 15.6. BioRad Laboratories, Inc.
• 15.7. DNA Script SAS
• 15.8. GeneCopoeia, Inc.
• 15.9. Merck KGaA
• 15.10. PerkinElmer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer